Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan for Diabetic Retinopathy in Type 2 Diabetes (DIRECT-Protect 2)
NCT00252694Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2001
- Primary completion
- Feb 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in diabetic retinopathy (DR) comparing Candesartan with Placebo (2 arms). Primary endpoint: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale at 5 years. Started Aug 2001; status: completed.
02
Drugs
candesartan
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT00252694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252694.